UiPath Introduces UiPath Maestro Flow, Delivering Developer-First Orchestration for Coding Agents

New orchestration capability lets builders use any coding agent to build, run, and govern complete business processes—no rewrite required to ship

UiPath, Inc. (NYSE: PATH), a global leader in business orchestration and automation, today announced UiPath Maestro™ Flow, a developer-first orchestration canvas combining the speed of modern, AI-native development with enterprise-grade durability and governance. Using Maestro Flow, builders can use supported coding agents to design, run, observe, and govern an end-to-end process as a single artifact, from prototype to production.

With the popularity of coding agents, enterprise builders can build AI agents quickly, but struggle to implement and run them as real business processes across systems. Without a critical layer of orchestration, process logic becomes fragmented, difficult to govern, and costly to maintain—prototypes cannot ship, work stalls while waiting on review, automations are not tracked, and the cost of experimentation itself becomes a brake on progress.

Maestro Flow closes that gap. Builders can use the coding agents they already rely on—including Claude Code, Cursor, GitHub Copilot, and Codex—to design, run, observe, and govern complete business processes as a single artifact, all from their native development environment, such as VS Code or UiPath Studio. It is a fast, code-first build experience directly on an enterprise-grade orchestration engine, so the version prototyped is the version that ships into production, without rebuilding or re-platforming.

Maestro Flow enables teams to build at prototype speed and run with production durability. Teams keep the code-first workflow they already use, while enterprises gain the execution, observability, and governance needed for production. Coordinating AI agents, robots, APIs, documents, and people within one flow, Maestro Flow runs on the same Maestro orchestration engine enterprises already trust.

"Enterprises don't have an agent problem; they have an orchestration problem," said Raghu Malpani, Chief Product and Technology Officer, UiPath . "With coding agents, it's never been easier to build an agent. But running a real business process, spanning agents, robots, systems, and people—and being able to prove what happened at every step—needs an orchestration layer that ties these together in a real business environment. Maestro Flow is that missing layer, and it runs on the durable, governed orchestration foundation in the UiPath Platform that our customers already trust."

Developers can get started today with UiPath Maestro Flow by clicking the "Try Now" button at www.uipath.com/product/maestro/flow . For those developers interested in trying out UiPath Maestro, UiPath is offering UiPath Maestro Lite, a lightweight option for processes that do not require extensive management, matching operational depth with the cost and criticality of the work.

About UiPath

UiPath (NYSE: PATH) is a leader in business orchestration and automation, trusted by organizations worldwide to transform enterprise complexity into intelligent, secure operations where AI agents reason, robots act, and people lead. Built for the modern enterprise and the world's most regulated industries, UiPath integrates automation, orchestration, AI, and testing into governed, scalable workflows—unlocking innovation at the speed of business while delivering the controls and compliance enterprise leaders demand. Visit www.uipath.com for more information.

Media Contact:
Christian Potts
UiPath
pr@uipath.com

Investor Relations Contact:
Allise Furlani
UiPath
investor.relations@uipath.com

News Provided by Business Wire via QuoteMedia

PATH
The Conversation (0)
Edgewater Wireless Reports Fiscal 2026 Year-End Results and Highlights Growing Semiconductor Execution and Industry Validation

Edgewater Wireless Reports Fiscal 2026 Year-End Results and Highlights Growing Semiconductor Execution and Industry Validation

(TheNewswire) August 28, 2026 Ottawa, Canada TheNewswire - Edgewater Wireless Systems Inc. (TSXV: YFI,OTC:KPIFF) (OTC: KPIFF) ("Edgewater" or the "Company"), the industry pioneer of AI-powered Wi-Fi Spectrum Slicing™ silicon solutions and IP, today reported its financial results for the year... Keep Reading...
Shareholder Update

Shareholder Update

BLACK DRAGON RESOURCE COMPANY PROVIDES CORPORATE UPDATE; TEXAS FRAC SAND ACQUISITION REMAINS ON TARGET, FULL LONQUIST REPORT ATTACHED, AND OPEN-MARKET SHARE BUYBACK TO BEGIN AUGUST 31 DALLAS, TX / ACCESS Newswire / August 27, 2026 / Black Dragon Resource Companies, Inc. (OTC PINK:BDGR) ("Black... Keep Reading...
First Three Holes of a 20,000-Meter Program Just Pushed a U.S. Antimony-Gold Resource Beyond Its Own Boundaries

First Three Holes of a 20,000-Meter Program Just Pushed a U.S. Antimony-Gold Resource Beyond Its Own Boundaries

American News Group News Commentary - In critical-minerals exploration, the most valuable drill results are often not the flashiest grades but the ones that appear where the model said nothing should be. That is what makes a new set of assays from a Nevada antimony-gold project worth a close... Keep Reading...
Freegold Intersects 3.59 g/t Au over 143.7 m including 141.3 g/t Au over 3.0 m as it advances Golden Summit PFS

Freegold Intersects 3.59 g/t Au over 143.7 m including 141.3 g/t Au over 3.0 m as it advances Golden Summit PFS

SIX RIGS ACTIVE AS GOLDEN SUMMIT ADVANCES TOWARD PFS INFILL DRILLING FOCUSED ON INCREASING CONFIDENCE IN THE HIGHER-GRADE AREA DISTRICT-SCALE GROWTH POTENTIAL REMAINS OPEN ALONG TREND Freegold Limited ("Freegold") (TSX: FVL,OTC:FGOVF) (OTCQX: FGOVF) reports additional drill results from its... Keep Reading...
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturingProgram builds on BriaCell's experience in metastatic... Keep Reading...

Interactive Chart

Latest Press Releases

Related News